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S270 Poster Session IIweek course of preemptive treatment with ganciclovir for pts at low
risk for CMV disease or prolonged reactivation.
Table 1. Demographics of all recipients of HCT from an HLA
matched sibling donor following a myeloablative preparative
regimen between 1996 and 2008
Pts withN5 (%)reactivation
onlyGCV
treatment*GCV
treatment*(no evidence
disease) 3wks 6wksTotal patients at risk 287(100) 83(29) 40(14) 43(13)
D1/R1 182(63) 55(30) 27(15) 28(15)
D1/R- 43(15) 3(7) 1(2) 2(5)
D-/R1 62(22) 25(40) 12(19) 13(21)
TBI 146(49) 39(47) 17(43) 22(51)
prophylactic steroids 122(42) 28(34) 17(43) 11(26)
**Treatment of GVHD ** 100(34) 26(31) 12(30) 14(33)
steroid 2 mg/kg 42(15) 10(12) 3(8) 7(16)
steroid 1 mg/kg 58(20) 16(19) 9(23) 7(16)
Median creatinine NA NA 1.1 1.3
median first PCR NA NA 940 1300
median maximum PCR NA NA 1300 4400*IV ganciclovir
** at time of first detected viremia.301
A PROSPECTIVE COMPARISON OF OUTCOMES AND RESOURCE UTILIZA-
TION IN PATIENTS WITH MYELOID MALIGNANCIES UNDERGOING ALLO-
GENEIC HEMATOPOIETIC CELL TRANSPLANTATION (ALLOHCT) USING
MYELOABLATIVE OR REDUCED INTENSITY CONDITIONING
Gupta, V.1, Panzarella, T.2, Li, L.2, Khan, J.1, Alibhai, S.3, Galal, A.1,
Kuruvilla, J.1, Lipton, J.1, Messner, H.1 1 Princess Margaret Hospital,
Toronto, ON, Canada; 2 Princess Margaret Hospital, Toronto, ON, Can-
ada; 3 Toronto General Hospital, ON, Canada
We conducted a prospective study to compare outcomes, resource
utilization and quality of life (QOL) in patients with myeloid malig-
nancies undergoing alloHCT using myeloablatove (MY) or reduced
intensity conditioning (RIC). (QOL data submitted separately).
Patients with myeloid malignancies with a suitable matched re-
lated or unrelated donor, fit to undergo alloHCT using MY or
RIC were eligible for this study. The study was non-randomized
and primarily designed to determine whether RIC was as effective
as MY for the treatment of myeloid malignancies. The selection of
MY or RIC regimen was at the discretion of the treating physician.
The primary end point was leukemia-free survival (LFS) at 1-year.
Secondary end points were non-relapse mortality (NRM), relapse,
overall survival (OS), resource utilization and QOL. Patients were
enrolled from Jan 2005 to Sep 2008. Of the 118 eligible patients,
115 (MY 51; RIC 64) consented to participate. The outcomes and re-
source utilization data were collected at day30, day100, day180 and
day365.
Transplant indications included: AML, 83; MDS, 16; and other
myeloidmalignancies,16. 87 patients were of high and 28 of standard
risk. Apart from age, both study cohorts were well matched for base-
line patient, disease and transplant related characteristics. The me-
dian age of patients undergoing RIC was significantly higher than
those undergoing MY regimens (59 vs. 41 yrs, p\0.0001).
By univariate analysis, there were no differences in the RIC and
MY cohorts for 1-year LFS (53% vs. 58%, p5 0.60) and OS (61%
vs. 58%, p5 0.82). The outcomes were similar in multivariate anal-
ysis with LFS (HR 0.82, p5 0.61) and OS (HR 0.79, p5 0.55). No
significant differences were observed in the cumulative risk of NRM
or relapse at 1-year. Disease risk stratification was the only signifi-
cant factor for LFS (HR for standard risk 0.42, p5 0.02) and OS
(HR 0.34, p5 0.008).
Medical resources utilization was similar during the first 100 days.
From day 100 to day 365, the RIC cohort required a significantlyhigher number of in-patient hospital days (p\0.001), higher num-
ber of outpatient visits (p\0.0001) and a higher number of platelet
transfusions (p\0.0001).
We conclude that disease biology rather than intensity of the con-
ditioning therapy is major determinant of outcomes of alloHCT in
patients with myeloid malignancies. The utilization of medical re-
sources is higher after 100 days in the patients undergoing RIC.
Long-term follow up of this study is in progress.302
KIR HAPLOTYPE MAY INFLUENCE CLINICAL OUTCOME FOLLOWING
HLA-MATCHED SIBLING HAEMOPOIETIC STEM CELL TRANSPLANTATION
Heatley, S.L.1,3, Mullighan, C.G.2, Sullivan, L.C.3, Brooks, A.G.3,
Szer, J.4, Bradstock, K.5, Schwarer, A.P.6, Bardy, P.G.1,7 1 Australian
Red Cross Blood Service, Adelaide, South Australia, Australia; 2 St Jude
Children’s Research Hospital, Memphis, TN; 3 University of Melbourne,
Melbourne, VC, Australia; 4 Royal Melbourne Hospital, Melbourne, VC,
Australia; 5 Westmead Hospital, Sydney, New South Wales, Australia;
6 The Alfred Hospital, Melbourne, VC, Australia; 7 Royal Adelaide Hospi-
tal, Adelaide, South Australia, Australia
Natural killer cell alloreactivity due to Killer cell Immunoglobu-
lin-like Receptors (KIR) repertoire has been reported to be advanta-
geous in haploidentical allogeneic haemopoietic stem cell
transplants (HSCT). Benefits include superior survival, reduced re-
lapse and graft versus host disease particularly in patients trans-
planted for Acute Myeloid Leukaemia (AML). However data from
HLA-matched sibling HSCT are inconsistent and recently other
models have been proposed to measure NK alloreactivity including
the missing ligand and KIR haplotype models.
We examined the association between KIR haplotype, relapse,
overall survival and acute graft versus host disease (aGvHD) in
a cohort of 147 HLA matched siblings undergoing HSCT. KIR
genotyping was by multiplex PCR-SSP and haplotypes were cate-
gorised as the A haplotype carrying the 2DL1, 2DL3, 3DL1,
2DS4 and framework genes, all other combinations were denoted
the B haplotype. Combinations of KIR haplotype were assigned to
each transplant according to the donor and then recipient haplo-
type ie AA-AA, AA-Bx, Bx-AA and Bx-Bx where Bx denotes either
BB or BA.
In the entire cohort relapse, overall survival and aGvHD were not
significantly associated with donor and recipient KIR haplotype.
However when only AML patients (n5 69) were considered AA do-
nors-Bx recipients had superior survival rates and those with AA-AA
the most inferior. Interestingly this was also true for grades II-IV
aGvHD, with AA-Bx having no aGvHD and AA-AA the most
(p5 0.032). Furthermore, when stratified to only include AML pa-
tients receiving myeloablative conditioning, an AA donor-AA recip-
ient had inferior overall survival (p5 0.015) and the most severe
aGvHD (p5 0.054).
KIR haplotype may influence the clinical outcome of HLA-
matched sibling HSCT, particularly in patients treated for Acute
Myeloid Leukaemia that had received myeloablative conditioning.303
UNMANIPULATED HLA-MISMATCHED/HAPLOIDENTICAL BLOOD AND
MARROW HEMATOPOIETIC STEM CELL TRANSPLANTATION
Huang, X. Peking University, Beijing, China
A novel approach to HLA mismatched/haploidentical blood and
marrow hematopoietic stem cell transplantation.
Peking University researchers developed a novel approach to
HLA-mismatched/haploidentical transplantation without in vitro
T cell depletion. More than 831 cases of haploidentical transplan-
tation have been fulfilled and the promising results have been
achieved.
Engraftment: Huang et al reported 171 patients underwent trans-
plantation with this protocol, all patients achieved hematopoietic re-
covery. There was no significant association between the extent of
HLA disparity and the time of myeloid or platelet recovry.
Multivariate analysis indicated that the number of CD34+ cells
(\2.19 106/kg) in allografts, and advanced disease stage were
Poster Session II S271independently associated with platelet engraftment.While in pediat-
ric patients only infused CD34+ cells/kg was significantly associated
with platelet engraftment.
Graft-versus-host disease: At days 100, the cumulative incidence
was 55.0% for grade II-IV aGVHD, and 23.1% for grade III-IV
aGVHD. While cGVHD 44.67%, with 21.3% for limited and
23.3% for extensive. In patients under 14 years old, the cumulative
incidence of aGVHDof grade II-IVwas 57.2%, and 13.8% for grade
III-IV.While cGVHD 56.7% for total and 29.5% for extensive. No
associations of HLA disparity with incidence and severity of GVHD
were found.
KIR ligand mismatch and a higher dose of CD56bright NK cells
(41.9 106/kg) in the allografts are associated with high incidence of
aGVHD, while a higher CD56dim/CD56bri NK cell ratio (more
than 8.0) in allografts was correlated with a decreased risk of III-
IV aGVHD.
Relapse Tranplant-related mortality and survival: The 3-year
probability of relapse in the standard-risk group was 11.9%
and 24.3% for AML and ALL and that in high-risk group was
20.2% and 48.5% for AML and ALL, respectively. The advanced
disease status, Higher CD4/CD8 in G-BM and delayed lympho-
cyte recovery at day 30 post transplantation are correlated with
increased relapse rate. While, a higher CD56dim/CD56bri NK
cell ratio (more than 8.0) was correlated with a decreased rate
of relapse. Modified DLI can be used to treat relapse of patients
after the protocol.
The TRM on day 100 in the standard- and high-risk groups was
6.8% and 5.9% for AML and 6.9% and 25.9% for ALL, respectively.
The 3-year probability of LFS for AMLwas 70.7% and 55.9% and
for ALL was 59.7% and 24.8% in the standard-risk and high-risk
groups, respectively.304
IMMUNOSUPPRESSIVE CYTOKINE GENE POLYMORPHISMS AND OUT-
COMES AFTER RELATED AND UNRELATED HEMATOPOIETIC CELL
TRANSPLANTATION
Xiao, H., Lai, X., Wu, G., Luo, Y., Shi, J., Tan, Y., Han, X., Zhu, X.,
Zhu, J., Xie, W., He, J., Cai, Z., Lin, M., Ye, X., Huang, H. The First
Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou,
Zhejiang, China
Background: Transforming growth factor-ß(TGFß) and IL10 are
pleiotropic regulatory cytokines in the immune system. Clinical
data and animal model suggest TGFß and IL10 can suppress
aGVHD. The present study was designed to test the influence of
gene polymorphisms of TGFß and IL10 on outcomes after related
and unrelated HSCT.
Methods:We analysed six single nucleotide polymorphisms (SNPs)
in three genes, TGFß1-509(C.T), +869 (T.C), TGFß1 receptor
II (TGFß1RII) +1167 (C.T) and IL10 -1082(A.G),
-819(T.C), -592(A.C), in a cohort of 138 pairs of recipients
and their unrelated donors and a second cohort of 102 pairs of recip-
ients and their HLA-identical sibling donors, who had undergone
HSCT from January 2001 to March 2009 at our center.
Results: (1) TGFß1 -509 T/T genotype in the donors side or T al-
lele-positive in the recipients side showed a significant protective ef-
fect on the occurrence of aGVHD and grade II-IV aGVHD in the
unrelated transplantation cohort (P\0.05). In the combined cohort,
the multivariate analysis confirmed that donors with TGFß1-509 T/
T genotype had a protective effect on the risk of aGVHD. (2) Both in
unrelated transplantation cohort and sibling transplantation cohort,
We found the IL10-819 C/C and -592 C/C genotype in either recip-
ients side or donors side were significantly associated with a higher
incidence of aGVHD (P\0.05). (3) In the combined cohort, the
promoter haplotypes of IL10 polymorphic features in positions
-1082, -819 and -592 had an influence on the occurrence of aGVHD
and death in remission. Recipients without A-T-A haplotype or were
transplanted from donors without A-T-A haplotype had a higher in-
cidence of aGVHD and death in remission than with A-T-A homo-
zygous or heterozygous. In multivariate analysis, recipients without
A-T-A haplotype was found to be associated with a higher risk of
aGVHD (RR5 0.764; P5 0.096) and grade II-IV aGVHD
(RR5 0.413; P5 0.009). (4) No significant association with
aGVHD was detected for the TGFß1 + 869, TGFß1RII +1167and IL10-1082 genotypes. No significant association was found be-
tween cytokine genes polymorphisms with cGVHD, relapse and
overall survival.
Conclusions:This is the first report of the relation of gene polymor-
phisms of IL10, TGFß1 and TGFß1RII to outcomes of allo-HSCT
within Chinese population. The results may provide useful informa-
tion to risk assessment, donor selection, and a guide for appropriate
immunosuppressive therapy.305
PTLD IN MINIATURE SWINE FOLLOWING NOVEL LOW INTENSITY CON-
DITIONING FOR HAPLOIDENTICAL HCT: THE MGH EXPERIENCE
Duran-Struuck, R.1, Teague, A.1, Crepeau, R.1, Matar, A.1,
Henakamp, I.1, Pathiraja, V.1, Veillette, G.1, Spitzer, T.R.2,
Sachs, D.H.1, Bronson, R.T.3, Huang, C.1 1 Massachusetts General Hospi-
tal (Harvard Medical School), Boston, MA; 2 Massachusetts General Hos-
pital (Harvard Medical School), Boston, MA; 3 Harvard Medical School,
Boston, MA
Haploidentical HCT (haplo-HCT) is a potent and potentially cu-
rative therapy for a number of lymphohematopoietic neoplasms.
Haplo-HCT has been limited by toxic conditioning regimens and
the development of lethal graft-versus-host disease (GVHD). Similar
to what has been observed in the clinic, myeloablative HCT out-
comes in the pig have a high incidence of GVHD. Less toxic, non-
myeloablative haplo-HCTs developed in our laboratory resulted in
a greatly reduced incidence and intensity of GvHD. However,
post-transplantation lymphoproliferative disease (PTLD) was often
observed following these novel reduced intensity conditioning proto-
cols. Haplo-HCT conditioning with 700-1000 cGy thymic irradia-
tion (TI), CD3 immunotoxin and 30-60 days of cyclosporine had
a 6% incidence ofGVHD (2 of 32) but was complicated by a 33% in-
cidence of PTLD (11 of 32). Of these 11 pigs, 2 resolved their PTLD
after cyclosporine was discontinued but then developed GVHD.
When thymic irradiation was eliminated from the protocol, no
PTLD was observed and GVHD was only observed in 2 of 24
(8.3%) transplanted pigs. Unfortunately this very mild preparatory
regimen without TI failed to consistently achieve successful long
term engraftment. In an attempt to decrease the incidence of
PTLD, avoid GVHD and increase haplo-HCT engraftment out-
comes, 100 cGy of total body irradiation (TBI) was introduced to
the protocol.Of 46 haplo-HCTrecipients, only 4 (\10%) developed
PTLD and 2/46 animals developed GVHD, one of which recovered
spontaneously. We also attempted to identify serum markers for di-
agnosingPTLDin our pigs. As it is observed in humans,we identified
lactate dehydrogenase (LDH), to be elevated in pigs prior to onset of
PTLD. In support of these findings, three porcine PTLD tumor cell
lines harvested from animals and passaged in vitro demonstrate
higher LDH levels compared to naı¨ve PBMCs. We conclude that:
(1) our current haplo-HCT protocol utilizing 100 cGy TBI, porcine
CD3 immunotoxin and 45 days of cyclosporine is relatively safe and
significantly reduces the incidence of PTLD; (2) stable engraftment
and multilineage chimerism can be achieved with minimal GVHD;
and (3) LDH is a clinically relevant serum marker for the diagnosis
of PTLD in the pig. These findings reinforce the pigmodel as a valu-
able tool for HCT translational studies.306
CLOFARABINE6 FLUDARABINE WITH IV BUSULFAN AND ALLOGENEIC
STEM CELL TRANSPLANTATION FOR RELAPSED, REFRACTORY MYELOID
LEUKEMIA (ML) AND MDS
Andersson, B.S., de Lima, M., Valdez, B.C., Thall, P.F., Worth, L.L.,
Popat, U., Jones, R.B, Shpall, E.J., Madden, T., McAdams, P.L.,
Alousi, A.M., Rondon, G., Kebriaei, P., Champlin, R.E. University of
Texas M.D. Anderson Cancer Center, Houston, TX
Clofarabine (Clo) is a nucleoside analog (NA) with improved an-
tileukemic efficacy compared with Fludarabine (Flu), previously
used with IV Busulfan (Bu) in reduced toxicity conditioning therapy
for Allo-SCT. In vitro studies of [Clo + Flu + Bu] demonstrated a su-
perior synergistic cytotoxicity compared with either [Clo + Bu] or
[Flu + Bu].We have now investigated [Clo6 Flu] with IV Bu in pre-
transplant conditioning.
